Neuropathic pain is considered the most difficult to manage, with many patients getting inadequate relief from the current pharmacotherapy. While many drugs have been added to the regimen, Lacosamide has emerged as a promising therapeutic option. This systematic review focuses on the efficacy and safety of lacosamide in adult patients with neuropathic pain. Databases such as PubMed, Embase, Scopus, Web of Science, and Cochrane were searched thoroughly for Randomized Controlled Trials (RCTs) published in English through November 2025. The Cochrane Risk of Bias 2 tool was used to assess the risk of bias in the included studies. Eight RCTs involving 976 participants with different neuropathic pain conditions met the inclusion criteria. Across the included studies, Lacosamide (200-600 mg/day) provided a modest reduction in their pain scores. However, it didn't have much of a positive impact on quality of life, limited function, adverse effects were common, and a high dropout rate was observed in several trials. Lacosamide might provide a modest analgesic benefit across multiple neuropathic conditions. But its extensive, long-term use requires more research to confirm its benefits, particularly the optimum dosing protocols.
1 January 2026 in Journal of Dental Anesthesia and Pain Medicine
IntroductionMigraine is a disabling neurological disorder often linked with neuroinflammation, with many patients experiencing only partial relief from existing pharmacological treatments. Omega-3 fatty acids and nano-curcumin, known for their anti-inflammatory and neuroprotective properties, are promising adjunctive or alternative strategies for migraine management. ObjectiveThis review aims to evaluate the combined efficacy of omega-3 fatty acids and nano-curcumin in reducing the frequency, duration, and intensity of migraine attacks, and to elucidate their potential mechanisms of action by modulating inflammatory and neuroprotective pathways. MethodsA total of 1,632 articles were initially retrieved through electronic database searches. Once duplicate records were removed, an additional search of reference lists from pertinent publications was performed. After screening the titles and abstracts, five studies were shortlisted for full-text assessment. ResultsThe combined use of omega-3 fatty acids and nano-curcumin significantly reduces the number, frequency, and severity of migraine attacks. This synergistic effect is attributed to their ability to modulate inflammatory and neuroinflammatory pathways, offering a promising adjunctive therapy. Current evidence suggests that the combination of omega-3 fatty acids and nano-curcumin results in a significant reduction in migraine frequency and severity compared to either supplement alone. The synergistic interaction between these agents enhances anti-inflammatory responses and neuronal protection, contributing to improved clinical outcomes and complementing conventional migraine therapies. ConclusionsThe concurrent use of omega-3 fatty acids and nano-curcumin demonstrates promising therapeutic potential in migraine management. Nonetheless, further large-scale, long-term clinical trials are warranted to validate these findings and to establish optimal dosage regimens and treatment durations.